Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients
| العنوان: | Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients |
|---|---|
| المؤلفون: | Enrico Vasile, Carmelo Tibaldi, G. Leticia Leon, Elisa Giovannetti, Armida D'Incecco |
| المساهمون: | Medical oncology laboratory, CCA - Innovative therapy |
| المصدر: | Journal of Cancer Research and Clinical Oncology, 141(7), 1189-1194. Springer Verlag Vasile, E, Tibaldi, C, Leon, G L, D'Incecco, A & Giovannetti, E 2015, ' Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients ', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1189-1194 . https://doi.org/10.1007/s00432-014-1880-3Test |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, CYP1B1, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Single-nucleotide polymorphism, Docetaxel, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Polymorphism (computer science), Carcinoma, Non-Small-Cell Lung, Internal medicine, Tumor Cells, Cultured, medicine, Carcinoma, Humans, neoplasms, Genetic Association Studies, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Hematology, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, body regions, Treatment Outcome, Chemotherapy, Adjuvant, Cytochrome P-450 CYP1B1, Female, Taxoids, business, medicine.drug |
| الوصف: | Cytochrome P450 1B1 (CYP1B1) is involved in the metabolism of anticancer agents; its overexpression was associated with resistance to docetaxel, a commonly used drug for second-line treatment of NSCLC. Several functional single nucleotide polymorphisms (SNPs) have been associated with CYP1B1 expression and activity. The objective of this study was to retrospectively evaluate the correlation of CYP1B1 SNPs with the outcome of NSCLC patients treated with docetaxel in second or third line.Associations between CYP1B1 4326CG and 4390AG polymorphisms with response, progression-free survival (PFS) and overall survival (OS) were estimated using Pearson χ(2) test, Kaplan-Meier curves and log-rank test; a multivariate analysis was performed using Cox proportional hazards modeling.A total of 65 advanced NSCLC patients were enrolled into the analysis. Median age was 66 years (range 46-81). Forty-nine patients were male; only five were never smokers. Performance status (PS) was 0 in 25 patients, 1 in 28 and 2 in 12. Histology was adenocarcinoma in 28 patients, squamous carcinoma in 22, other NSCLC in the remaining 15. At univariate analysis, stage and CYP1B1 4326CG SNPs are associated with PFS, while PS and CYP1B1 4326CG SNPs correlated with OS. In particular, patients with CYP1B1 4326-GG genotype had shorter PFS and OS than patients with other genotypes (PFS 1.80 vs. 2.70 months, p = 0.12; OS 3.63 vs. 9.83 months, p = 0.039). CYP1B1 4326CG SNPs were also associated with response rate. Multivariate analysis confirmed the independent prognostic/predictive role of CYP1B1 4326CG SNPs on OS (p = 0.042) with only a trend for PFS (p = 0.083).CYP1B1 4326CG polymorphism emerged as possible prognostic/predictive marker of activity and efficacy of docetaxel in NSCLC patients. |
| تدمد: | 0171-5216 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5595da0c67b8409b2e8a1b7b1b23d1Test https://research.vumc.nl/en/publications/96018efa-575a-443a-b58a-d1486c35ebb8Test |
| حقوق: | RESTRICTED |
| رقم الانضمام: | edsair.doi.dedup.....0c5595da0c67b8409b2e8a1b7b1b23d1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 01715216 |
|---|